VuCOMP, Maker of M-Vu Automated Breast Density Measurement Technology, Sponsors Are You Dense MusicFest
PLANO, Texas--(BUSINESS WIRE)--VuCOMP, Inc., leading developer of advanced computer vision systems for the detection of breast cancer, announced today that it will be a sponsor of the annual “Are You Dense MusicFest” on June 28, 2014 at the historic Palace Theater and Performing Arts Center in Waterbury, CT. Proceeds from the event benefit Are You Dense Inc., a global organization founded by Dr. Nancy M. Cappello dedicated to informing the public about dense breast tissue and its significance for the early detection of breast cancer. Clinical studies have shown that dense breasts can make breast cancer detection in a mammogram more difficult by potentially masking malignant masses. As a result of advocacy from Are You Dense and their supporters, 17 states now have breast density notification legislation, and more states have legislation pending. Federal legislation is also under consideration.
“We’re very pleased that VuCOMP is participating in our MusicFest as a sponsor as well as developing important breast density measurement technologies for radiologists. In doing so, helping radiologists to communicate a woman's breast tissue composition and opening up discussions about her personalized screening surveillance options.”
VuCOMP has responded to the need for standardization and automation of breast density measurement. In December 2013, the company received FDA approval for and released M-Vu Breast Density which automatically and rapidly evaluates mammograms in much the same manner as experienced radiologists do: by analyzing the structure and texture of the tissue, rather than simply estimating total fibroglandular volume. The algorithms quantify areas with a dense appearance which could hide cancer and convert this to categories corresponding to the recently updated BI-RADS standard. This exclusive approach using appearance-based analysis provides useful adjunctive information.
Are You Dense Inc. Founder and Director Nancy Cappello, Ph.D. commented, “We’re very pleased that VuCOMP is participating in our MusicFest as a sponsor as well as developing important breast density measurement technologies for radiologists. In doing so, helping radiologists to communicate a woman's breast tissue composition and opening up discussions about her personalized screening surveillance options.”
VuCOMP President and CTO Jim Pike said, “Are You Dense has been very effective in raising public awareness of the breast density issue. In sponsoring their MusicFest we hope to support their efforts as they continue to build momentum for this important endeavor.”
In addition to M-Vu Breast Density, clinics around the world are using the company’s M-Vu® Computer-Aided Detection (CAD) for mammography. M-Vu CAD analyzes mammograms to mark areas consistent with breast cancer using sophisticated mathematical algorithms.
About VuCOMP, Inc.
VuCOMP, Inc. leads the way in setting a new standard for CAD and automated breast density measurement. The company is dedicated exclusively to developing advanced cancer detecting technologies. VuCOMP’s engineering team has worked together since 1986, pioneering some of the world’s most advanced computer vision systems. For more information, please visit www.vucomp.com.
About Are You Dense Advocacy Inc. (www.AreYouDenseAdvocacy.org)
Are You Dense Advocacy, Inc. is a 501(c)(4) nonprofit charity with the mission of employing regulatory, state and federal legislation effort to standardize the communication of breast tissue to women. The charity was founded by Nancy. M. Cappello, PhD in 2011, after her successful landmark legislation advocacy as Connecticut became the first state in the country to standardize the communication of dense breast tissue through the mammography report. Additionally, Connecticut has also enacted expanded insurance screening coverage for women with dense breast tissue.
Dr. Cappello also founded Are You Dense, Inc. (www.AreYouDense.org) a 501 (c)(3) public charity, after her advanced stage breast cancer diagnosis within weeks of a normal mammogram report and a decade of normal reports preceding her diagnosis. Its mission is to educate the public about the risks and screening challenges of dense breast tissue.